Following the receipt of all required regulatory approvals, Lonza has completed the acquisition of Capsugel from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion. The acquisition is expected to be accretive to Lonza’s core earnings per share in the first full year post closing.
 
This acquisition is in line with Lonza’s stated strategy to accelerate growth and deliver value along the healthcare continuum by complementing its existing offerings and by opening up new market opportunities in the pharma and consumer healthcare and nutrition industries.
 
With the acquisition of Capsugel, Lonza adds a trusted brand with a large breadth of technologies that it believes will expand the market reach of both companies’ contract development and manufacturing organization (CDMO) and products businesses. It also supports Lonza’s strategic ambition of getting closer to the patient and end consumer.
 
“Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance,” said Richard Ridinger, Lonza’s CEO. “All of these aspects will facilitate a seamless integration.”
 
Capsugel’s business will continue to operate in its existing structure until the full integration has been completed.